FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular, to ophthalmology and pharmacy, and is intended for reduction of intraocular pressure. Method includes introduction of specially elaborated medications from the group of angiotensin-converting enzyme into conjunctival cavity. Medication is characterised by the following: inhibitor is introduced in composition of calcium-phosphate biodegradable nanoparticles with radius 30-350 nm and in concentration 0.1% - 3%.
EFFECT: selection of nanoparticle size and corresponding concentration of said preparations, when they are introduced into conjunctival cavity, makes it possible to ensure enhance of prolongation of effect of intraocular pressure reduction with reduction of risk of local and general side effects, including application of prodrug forms of said inhibitors.
6 ex
Title | Year | Author | Number |
---|---|---|---|
AGENT FOR REDUCING INTRAOCULAR PRESSURE AND METHOD OF USE THEREOF | 2022 |
|
RU2815996C1 |
AGENT FOR TREATMENT OF EYE DISEASES AND METHOD OF ITS USE | 2016 |
|
RU2657780C2 |
METHOD FOR TREATMENT AND PROPHYLAXIS OF OPHTHALMIC DISEASE ASSOCIATED WITH EYE TISSUE ISCHEMIA | 2004 |
|
RU2268722C2 |
METHOD OF TREATING EYE DISEASES ACCOMPANIED BY OXIDATIVE STRESS | 2014 |
|
RU2577236C1 |
PHARMACEUTICAL COMPOSITION FOR TREATING EYE DISEASES AS A RESULT OF MICROCIRCULATION DISORDERS AND/OR INFLAMMATORY PROCESSES | 2004 |
|
RU2277411C1 |
PHARMACEUTICAL COMPOSITION FOR LOCAL APPLICATION IN TREATING INFLAMMATORY EYE DISEASES AND METHOD FOR USING IT | 2012 |
|
RU2508123C1 |
METHOD FOR PREDICTION OF DEVELOPING NEURODEGENERATIVE DISEASES, UNDERLYING THE PATHOGENESIS OF WHICH IS GAMMA-SYNUCLEINOPATHY | 2018 |
|
RU2703430C1 |
ANGIOTENSIN CONVERTING ENZYME INHIBITORS FOR TREATING OPTIC NEUROPATHY OR CONGENITAL OPTIC ATROPHY | 2013 |
|
RU2658461C2 |
METHOD FOR PREPARING PATIENTS BEFORE OPERATION TO SURGICAL TREATMENT OF CATARACT COMPLICATED WITH GLAUCOMA | 2006 |
|
RU2314069C1 |
METHOD FOR EYE ISCHEMIA SIMULATION | 2016 |
|
RU2620014C1 |
Authors
Dates
2013-01-20—Published
2011-11-24—Filed